Treatment progress of relapsed/refractory peripheral T-cell lymphoma / 白血病·淋巴瘤

Peripheral T-cell lymphoma (PTCL) is a highly heterogeneous disease with numerous subtypes, and the overall prognosis is poor, especially in relapsed/refractory patients, and the patients are generally older with limited treatment options that can be tolerated. At the 64th American Society of Hematology (ASH) Annual Meeting in 2022, studies on relapsed/refractory PTCL include the combination of epigenetic agents or combination of immune checkpoint inhibitors, CD30 antibody-drug conjugate (ADC) brentuximab vedotin combined with chemotherapy, targeted drugs PI3K inhibitors and JAK1 inhibitors, etc., providing more choices and opportunities for relapsed/refractory patients.